Does surgical prophylaxis with teicoplanin constitute a therapeutic advance?

Area of Science:

• Infectious Diseases
• Surgical Prophylaxis
• Pharmacology

Background:

• Antibiotic prophylaxis is standard in many surgeries, but its use in clean non-implant surgery remains debated.
• Glycopeptides are alternatives to cephalosporins for Gram-positive infections and beta-lactam allergies.
• Institutional resistance rates of Staphylococcus aureus and epidermidis should guide glycopeptide use.

Purpose of the Study:

• To review clinical studies on glycopeptide use for antibiotic prophylaxis in clean surgical procedures.
• To evaluate the efficacy and suitability of glycopeptides, particularly teicoplanin, in surgical prophylaxis.

Main Methods:

• Review of clinical trials and studies focusing on glycopeptide prophylaxis in clean surgery.
• Analysis of efficacy, safety, and pharmacokinetic profiles of glycopeptides, comparing teicoplanin and vancomycin.

Main Results:

• Glycopeptides are effective alternatives for Gram-positive bacteria, including methicillin-resistant strains.
• Teicoplanin demonstrates favorable properties like tissue penetration, low toxicity, and a long half-life, enabling single-dose administration.
• Clinical trials confirm teicoplanin's efficacy in orthopedic, cardiac, vascular, and dental surgeries.

Conclusions:

• Teicoplanin is a suitable and potentially preferable glycopeptide for peri-operative antibiotic prophylaxis in clean surgery.
• The choice of glycopeptide should consider institutional resistance patterns and patient-specific factors.
• Evidence supports the use of teicoplanin for preventing surgical site infections in various clean procedures.